Spots Global Cancer Trial Database for Stereotactic Radiotherapy Plus Temozolomide for Refractory Brain Metastases

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Stereotactic Radiotherapy Plus Temozolomide for Refractory Brain Metastases

Official Title: Fractionated Stereotactic Radiotherapy Combined With Temozolomide for Refractory Brain Metastases: A Single-arm, Single-center Phase II Trial

Study ID: NCT02654106

Conditions

Brain Metastases

Interventions

Fractionated Stereotactic Radiotherapy

Temozolomide

Study Description

Brief Summary: This clinical trial was designed to investigate the efficiency and toxicity of fractionated stereotactic radiotherapy(FSRT) combined with Temozolomide(TMZ) for refractory brain metastases.

Detailed Description: This is a single-arm, single center, phase II trial to investigate the feasibility and toxicity of FSRT plus TMZ for refractory brain metastases, which are defined as A: multiple brain metastases(≥3 lesions); B: large brain metastases(with one lesion's volume is no smaller than 6cc or the longest diameter is no shorter than 3cm); C: meningeal metastases.